Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 07, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback:
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,193.44 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.10% of total voting rights).
- Shares in Issue: 5,212,510,927 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 800,000 repurchased shares. Consequently, the total number of shares in issue was adjusted to 5,212,510,927.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory notification of a capital transaction and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the repurchase (800,000 shares at 1,193.44 pence) against cash flow statements in the most recent 20-F filing.
- Confirm the updated share count of 5,212,510,927 for calculating ownership percentages under Disclosure and Transparency Rules.
- Review the impact of the 9.10% Treasury share holding on future earnings per share (EPS) calculations.